Iol Chemicals & Pharmaceuticals Ltd. · NSE:IOLCP
Iol Chemicals & Pharmaceuticals — Q2 FY2021 Earnings Presentation
24 slides from Iol Chemicals & Pharmaceuticals's earnings presentation, November 2020
Slide 1: IOL Chemicals and Pharmaceuticals Limited Investor Presentation
IOL Chemicals and Pharmaceuticals Limited Investor Presentation November 2020 1
Slide 2: Disclaimer
Disclaimer This information may contain certain forward-looking statements/details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views ex
Slide 3: About IOL Chemicals and Pharmaceuticals Limited
About IOL Chemicals and Pharmaceuticals Limited Incorporated in 1986, IOLCP is one of the leading APls / bulk drugs R&D Centre is approved by Department of Scientific and Industrial company and is a significant player in the field of specialty chemicals Research (DSIR) and a captive co-generation un
Slide 4: Key Highlights
Key Highlights Largest manufacturer of Ibuprofen with ~35% Global Team size of 1,950 employees share Largest producer of Ethyl Acetate at Single Location Only company world wide being backward integrated in India for Ibuprofen 2nd Largest producer of Iso Butyl Benzene (IBB) with Zero Discharge Efflu
Slide 5: Professional Board of Directors backed by a Strong Team
Professional Board of Directors backed by a Strong Team Rajender Mohan Malla Vikas Gupta (Chairman and Independent Director) (Executive Director) He has very distinguished career of four decades. He had held He is academically equipped with the knowledge and possesses top and significant decision-ma
Slide 6: Our Journey
Our Journey Commenced Ethyl Production of Unit-01 Ibuprofen Incorporated 1991 Acetate 1998 Ibuprofen 2006 (Dedicated) Started acetic acid Commenced Acetic Co-Generation 1986 & Listing on BSE 1996 2000 2007 Anhydride Plant Unit-06 IBB, MCA and Acetyl Pantoprazole Unit-03 Multi Chloride and 2020 (Dedi
Slide 7: Our Strong Global reach spread across 80 countries
Our Strong Global reach spread across 80 countries Argentina China Spain Netherlands Thailand Vietnam Bangladesh UAE Germany Nigeria Finland Uruguay Belgium Italy Indonesia Peru Switzerland UK Brazil Egypt Iran South Africa Portugal Kenya 7
Slide 8: Certifications and Accreditations
Certifications and Accreditations • Approved USFDA Ibuprofen facility since 2015, recertified in 2019 • EUGMP Certification in 2013, 2017 & Recertification in 2020 • Certificate of Suitability from EDQM for IBUPROFEN, CEP No. 316-2008 • Certificate of Suitability from EDQM for LAMOTRIGINE, CEP No. 0
Slide 9: Business Segment - Active Pharma Ingredients (APIs)
Business Segment - Active Pharma Ingredients (APIs) IOLCP’s APIs Revenue Share – 65% of total revenue Product Name Ibuprofen Metformin Clopidogrel Pantoprazole UDCA Lamotrigine Fenofibrate Capacity 12,000TPA 11,200TPA 180TPA 240TPA Therapeutic Area NSAIDS* Anti-diabetic Anti Platelet Acid Control Li
Slide 10: Strong Customer base across Diversified Industries
Strong Customer base across Diversified Industries Pharmaceuticals 10
Slide 11: Business Segment – Specialty Chemicals
Business Segment – Specialty Chemicals IOLCP’s Chemicals Revenue Share – 35% of total revenue Ethyl Acetate Iso Butyl Benzene Acetyl Chloride Mono Chloro Acetic Acid Product Name C4H8O2 C10H14 CH3COCl CICH2COOH Capacity 87,000TPA 12,000TPA 5,200TPA 7,200TPA % Revenue of total income 24.76% 8.07% 2.0
Slide 12: Strong Customer base across Diversified Industries
Strong Customer base across Diversified Industries Chemicals 12
Slide 13: Manufacturing Facility spread across 88 Acres at a Single Location
Manufacturing Facility spread across 88 acres at a Single Location with GMP approved guidelines API manufactured in batch manner and intermediates & Specialty chemicals in continuous product Research & Development 1 delivery manner based on DCS technology R&D work is carried out at the facility 2 24
Slide 14: Our Core Capabilities
Our Core Capabilities Technology • Blend skills of chemistry and engineering with latest tools & techniques for benchmarks achieved in API & Chemical products • Asia Pacific's first continuous dual technology (Green Chemistry) for MCA and Acetyl Chloride Strong Manpower • Operations of the company a
Slide 15: Location Benefits
Location Benefits Connectivity • Unit is well connected with State Highway and National Highway • Proximity to railway station and Dry port • Connected through road/rail with airports Single Site Location • Company is enjoying economics of scale • Pharmaceuticals segment is backward integrated with
Slide 16: Our Core Sustainability Pillars
Our Core Sustainability Pillars EHS Policy Economical & Social Responsibilities Environmental Responsibilities • Strive to minimize the adverse impact on • Assets and Capital Management & Utilization • State & central pollution control board & MoEF environment, health and Safety by upgrading • Custo
Slide 17: Key Financial Summary
Key Financial Summary Financial Summary Financial Summary (Q2FY21) (Q2FY20) 538.0 Total Income 452.4 Total Income Quarterly Summary 175.8 EBITDA 136.3 EBITDA (INR Cr) 127.0 PAT 87.7 PAT 17 All Profits and Total Income include Other Income
Slide 18: Financial Performance – Quarterly & Half Yearly
Financial Performance – Quarterly & Half Yearly Revenues & Margins* – Half Yearly & Quarterly Segmental EBIT % 2,000.0 46.0% 50.0% 45.0% 20.0% 44.2% 41.7% 1,800.0 45.0% 18.0% 46.3% 40.0% 42.8% 1,600.0 43.8% 40.0% 41.0% 41.8% 16.0% 1,400.0 32.7% 33.2% 35.0% 35.0% 30.0% 14.0% 30.1% 1,200.0 30.0% 30.0%
Slide 19: Financial Performance - Annual
Financial Performance - Annual Revenues & Margins* – Annual Margin* Expansion – Over the Years 2,000.0 1,910.5 50.0% 50.0% Gross margin % 1,800.0 1,695.7 45.0% 44.3% 45.0% 44.3% 11.3% 1,600.0 40.0% 40.0% EBITDA % 1,400.0 32.9% 38.2% 35.0% 35.0% 32.9% 29.7% 30.9% 1,200.0 30.0% 30.0% 16.3% 24.8% 30.9%
Slide 20: Segmental Breakup
Segmental Breakup Product wise Segmentation Geographical wise Segmentation 35.0% 66.0% 2020 2020 64.0% 34.0% 32.7% 61.6% 2019 2019 66.3% 38.4% 35.9% 64.4% 2018 2018 63.2% 35.6% 43.8% 68.0% 2017 2017 56.0% 32.0% Chemical Pharmaceutical Domestic Export 20
Slide 21: Financial Summary – Statement of Profit and Loss
Financial Summary – Statement of Profit and Loss P&L (INR Crs) FY17 FY18 FY19 FY20 Q2FY20 Q2FY21 H1FY20 H1FY21 Revenues 710.7 983.3 1,685.3 1,894.5 449.0 533.5 941.8 993.6 Other Income 1.3 6.3 10.4 16.0 3.4 4.5 6.7 10.3 Total Income 711.9 989.6 1,695.7 1,910.5 452.4 538.0 948.5 1,003.9 Cost of Goods
Slide 22: Financial Summary – Balance Sheet
Financial Summary – Balance Sheet Balance Sheet (INR Crs) FY18 FY19 FY20 H1FY21 Share Capital 56.2 56.9 56.9 58.7 Other Equity 159.5 417.5 756.7 1036.1 Shareholder's Funds 215.7 474.3 813.5 1094.8 Long Term Debt 258.1 189.9 0.0 0.0 Short Term Debt 135.3 67.7 55.9 21.4 Current Maturities 28.5 26.4 0.
Slide 23: Shareholder Information
Shareholder Information Stock Data (As on 10th November, 2020) Institutional Holders (%) Market Capitalization(₹) 3,808.81 Crs Stitching Depositary APG Emerging Markets Equity 1.16% Pool Face Value(₹) 10.0 Morgan Stanley Asia Pte 1.11% 52-Week High(₹) 898.4 Others 4.13% 52-Week Low(₹) 147.3 Total 6.
Slide 24: Thank You
Thank You For further details: Mr. Pardeep Kumar Khanna , CFO Email: pardeepkhanna@iolcp.com Phone: +91-161-2225531-35 24
IOL Chemicals and Pharmaceuticals — Q2 FY2021 Earnings Presentation on 6ix